For research use only. Not for therapeutic Use.
Livmoniplimab (ABBV-151; ARGX-115) is a potent, humanized monoclonal antibody against the LRRC32 (GARP)/TGFβ1 complex. Livmoniplimab blocks LRRC32-mediated latent TGFβ1 activation and release. Livmoniplimab has potential in cancer research as a single anticancer agent or in combination with an anti-PD-1 mAb to inhibit locally advanced or metastatic solid tumors (NCT03821935)[1][2][3][4].
| Catalog Number | I041585 |
| CAS Number | 2412004-88-5 |
| Purity | ≥95% |
| Reference | [1]. Li A, et al. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity. J Immunother Cancer. 2022 Sep;10(9):e005433. [2]. Roda D, et al. Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort[J]. 2024. |
